| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2006PNAS..10316870H |
| P356 | DOI | 10.1073/PNAS.0606509103 |
| P932 | PMC publication ID | 1629087 |
| P698 | PubMed publication ID | 17077147 |
| P5875 | ResearchGate publication ID | 6719703 |
| P50 | author | Yiguo Hu | Q59549068 |
| P2093 | author name string | Francis Y Lee | |
| Shaoguang Li | |||
| Sarah Swerdlow | |||
| Roberto Weinmann | |||
| Theodore M Duffy | |||
| P2860 | cites work | Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias | Q28246193 |
| Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling | Q28365521 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML | Q29614278 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo | Q29619355 | ||
| Overriding imatinib resistance with a novel ABL kinase inhibitor | Q30014844 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop | Q34075619 | ||
| Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. | Q34333693 | ||
| Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia | Q34546468 | ||
| Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies | Q34564857 | ||
| Punish the parent not the progeny. | Q35940421 | ||
| The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity | Q36368162 | ||
| p53 in chronic myelogenous leukemia in acute phase | Q37550931 | ||
| Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. | Q40458599 | ||
| The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase | Q40835186 | ||
| Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. | Q43775891 | ||
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro | Q43833442 | ||
| Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation | Q43977712 | ||
| Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases | Q44189751 | ||
| Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. | Q44224219 | ||
| BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. | Q44267685 | ||
| Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia | Q44851706 | ||
| A tail of two src's: mutatis mutandis | Q45248634 | ||
| Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia | Q46466215 | ||
| Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. | Q53464437 | ||
| The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia | Q73795156 | ||
| Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow | Q77531813 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 16870-16875 | |
| P577 | publication date | 2006-10-31 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice | |
| P478 | volume | 103 |
| Q35112252 | A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. |
| Q36135727 | AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow |
| Q28540033 | ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance |
| Q36835733 | Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells |
| Q47113874 | Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy |
| Q34547402 | Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients |
| Q39663467 | Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr–Abl positive cell lines in vitro and in vivo |
| Q61449792 | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications |
| Q35990624 | Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia |
| Q35931271 | Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond |
| Q34117463 | Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival |
| Q54655112 | Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias? |
| Q33988398 | Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase |
| Q35441406 | BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia |
| Q33806036 | BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells |
| Q36970694 | BCR-ABL-transformed GMP as myeloid leukemic stem cells |
| Q39974408 | BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia |
| Q37531026 | BCR/ABL can promote CD19+ cell growth but not render them long-term stemness |
| Q33947776 | Bcl2 is not required for the development and maintenance of leukemia stem cells in mice. |
| Q46774789 | Bcr-Abl induces autocrine IGF-1 signaling |
| Q33442587 | Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report |
| Q37810115 | Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia |
| Q36463738 | CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1 |
| Q34251497 | CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells |
| Q55016663 | CML Mouse Model Generated from Leukemia Stem Cells. |
| Q37010433 | Cancer induction by restriction of oncogene expression to the stem cell compartment |
| Q38133575 | Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era. |
| Q24622397 | Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q42687340 | Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. |
| Q37836936 | Chronic myeloid leukemia stem cells and developing therapies |
| Q35102414 | Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia |
| Q90262529 | Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit |
| Q27667482 | Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 |
| Q37767357 | Critical molecular pathways in cancer stem cells of chronic myeloid leukemia |
| Q27025242 | Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q37650203 | Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q42381521 | Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia |
| Q58921972 | DNA Microarray Assay Helps to Identify Functional Genes Specific for Leukemia Stem Cells |
| Q33384766 | Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial |
| Q34335004 | Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias |
| Q43178572 | Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice |
| Q42017483 | Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia |
| Q37308308 | Differential regulation of myeloid leukemias by the bone marrow microenvironment |
| Q38782370 | Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities |
| Q36780139 | Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. |
| Q35651730 | Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model |
| Q36445910 | Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. |
| Q33597663 | Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor |
| Q37450433 | Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells |
| Q34596305 | Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. |
| Q46755224 | Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors |
| Q35987068 | Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice |
| Q42223517 | Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Q35571035 | Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q34972855 | From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond |
| Q34062313 | Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells |
| Q53197147 | Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models. |
| Q36598249 | GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2 |
| Q47210315 | GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways |
| Q33753325 | Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling |
| Q35849333 | HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells |
| Q35176353 | HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation |
| Q42110946 | HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells |
| Q38166527 | Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies |
| Q34157874 | Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia |
| Q28393898 | Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells |
| Q37697852 | IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. |
| Q39255906 | IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development |
| Q36948612 | IRF-4 functions as a tumor suppressor in early B-cell development |
| Q36240238 | Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells |
| Q35900937 | Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. |
| Q42178606 | Inhibitor mediated protein degradation. |
| Q37303829 | Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice |
| Q90702236 | Integrin α6 mediates drug resistance of acute lymphoblastic B-cell leukemia |
| Q36799469 | Is phosphoproteomics ready for clinical research? |
| Q35126258 | Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. |
| Q26849792 | Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors |
| Q28484079 | LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells |
| Q36007673 | Leukemia stem cells in a genetically defined murine model of blast-crisis CML. |
| Q53293069 | Leukemia stem cells. |
| Q36488720 | Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo |
| Q33921399 | Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia |
| Q36508969 | Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells |
| Q30009317 | Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy |
| Q37836923 | Mechanisms of resistance to BCR-ABL kinase inhibitors. |
| Q92277650 | Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib |
| Q35719210 | Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells |
| Q37825832 | Molecular and cellular bases of chronic myeloid leukemia |
| Q37283128 | Molecular biology of bcr-abl1-positive chronic myeloid leukemia |
| Q33770326 | Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers |
| Q26828528 | Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells |
| Q37925098 | Molecular pathology of tumor-initiating cells: lessons from Philadelphia chromosome-positive leukemia |
| Q38164164 | Molecular signatures of chronic myeloid leukemia stem cells |
| Q37995194 | Mouse models as tools to understand and study BCR-ABL1 diseases. |
| Q42721777 | Murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders |
| Q38046320 | Myeloproliferative neoplasm animal models |
| Q83186138 | NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic |
| Q34087767 | Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo |
| Q55016655 | New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia. |
| Q38055491 | Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia |
| Q37698640 | Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia |
| Q36758024 | Oncogenic signaling: new insights and controversies from chronic myeloid leukemia |
| Q36384328 | Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway |
| Q51747038 | Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. |
| Q42679299 | PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β. |
| Q33608760 | PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice |
| Q24650730 | Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells |
| Q41843107 | Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia |
| Q37862648 | Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives |
| Q38016343 | Philadelphia-positive acute lymphoblastic leukemia: current treatment options |
| Q39211921 | Potential role of Wnt/β-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between β-catenin and BCR-ABL. |
| Q37816960 | Preclinical development of molecular-targeted agents for cancer |
| Q24607114 | Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia |
| Q38028778 | Pushing the limits of targeted therapy in chronic myeloid leukaemia. |
| Q35459525 | Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers |
| Q92430952 | Repurposing dasatinib for diffuse large B cell lymphoma |
| Q27028181 | Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options |
| Q35132225 | Right on target: eradicating leukemic stem cells |
| Q35169570 | Role of Pten in leukemia stem cells |
| Q38842352 | Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells. |
| Q35943938 | Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia |
| Q28087213 | Secondary mutations as mediators of resistance to targeted therapy in leukemia |
| Q95322301 | Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia |
| Q28248761 | Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases |
| Q36116937 | Src kinase signaling in leukaemia |
| Q37059746 | Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia |
| Q26799954 | Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia |
| Q35459748 | Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors |
| Q38095422 | Stem cell maintenance and disease progression in chronic myeloid leukemia |
| Q37027402 | Strategies for overcoming imatinib resistance in chronic myeloid leukemia |
| Q28271278 | Survival regulation of leukemia stem cells |
| Q39744014 | TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia |
| Q37752572 | Targeted therapy of chronic myeloid leukemia |
| Q42800089 | Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. |
| Q37144023 | Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers |
| Q52307146 | Targeting of nucleotide-binding proteins by HAMLET--a conserved tumor cell death mechanism. |
| Q57292631 | Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells |
| Q37272565 | Targeting the leukemic stem cell: the Holy Grail of leukemia therapy |
| Q36129530 | The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells |
| Q28551057 | The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies |
| Q34750582 | The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues |
| Q33798573 | The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients |
| Q30356398 | The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors |
| Q37909375 | The clinical and therapeutic implications of cancer stem cell biology |
| Q37175318 | The diverse functions of Src family kinases in macrophages |
| Q38071041 | The hematopoietic stem cell niche--home for friend and foe? |
| Q24294830 | The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization |
| Q91011024 | The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia |
| Q90281838 | The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis |
| Q37018640 | Toward 'SMART' stem cells |
| Q33369693 | Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation |
| Q35627994 | Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells |
| Q34272962 | Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia |
| Q37663655 | Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice |
| Q38710822 | Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells |
| Q46345796 | beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia |
| Q34632798 | Δ12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice |
| Q36140375 | β-Arrestin2 mediates the initiation and progression of myeloid leukemia. |
Search more.